US8105375B2 - Method for implanting a cardiovascular valve - Google Patents
Method for implanting a cardiovascular valve Download PDFInfo
- Publication number
- US8105375B2 US8105375B2 US12/016,168 US1616808A US8105375B2 US 8105375 B2 US8105375 B2 US 8105375B2 US 1616808 A US1616808 A US 1616808A US 8105375 B2 US8105375 B2 US 8105375B2
- Authority
- US
- United States
- Prior art keywords
- support member
- expandable support
- valve
- desired location
- substantially dehydrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 10
- 210000000748 cardiovascular system Anatomy 0.000 claims abstract description 42
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 8
- 238000013459 approach Methods 0.000 claims description 6
- 238000002788 crimping Methods 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 230000005865 ionizing radiation Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 description 49
- 210000004115 mitral valve Anatomy 0.000 description 29
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 210000003516 pericardium Anatomy 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 210000005240 left ventricle Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 210000005241 right ventricle Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000560 biocompatible material Substances 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 210000005246 left atrium Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000000591 tricuspid valve Anatomy 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 210000001765 aortic valve Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000001951 dura mater Anatomy 0.000 description 3
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000005248 left atrial appendage Anatomy 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000003102 pulmonary valve Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 210000002620 vena cava superior Anatomy 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003698 chordae tendineae Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 210000004971 interatrial septum Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003540 papillary muscle Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000002073 venous valve Anatomy 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QFSNCROGCLRZHC-UHFFFAOYSA-N 2,3-dihydroxypropoxyboronic acid Chemical compound OCC(O)COB(O)O QFSNCROGCLRZHC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920006309 Invista Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920008262 Thermoplastic starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000872 anti-mineralization Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005247 right atrial appendage Anatomy 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004628 starch-based polymer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/243—Deployment by mechanical expansion
- A61F2/2433—Deployment by mechanical expansion using balloon catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/243—Deployment by mechanical expansion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/2436—Deployment by retracting a sheath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0095—Packages or dispensers for prostheses or other implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9522—Means for mounting a stent or stent-graft onto or into a placement instrument
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9522—Means for mounting a stent or stent-graft onto or into a placement instrument
- A61F2/9524—Iris-type crimpers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0073—Quadric-shaped
- A61F2230/0078—Quadric-shaped hyperboloidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0092—Means for cleaning prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
- Y10T29/49908—Joining by deforming
- Y10T29/49925—Inward deformation of aperture or hollow body wall
Definitions
- the present invention relates generally to a method for treating and improving the function of cardiovascular valves, and more particularly to a method for implanting a cardiovascular valve within the cardiovascular system of a subject.
- a number of implantable bioprosthetic devices are currently being used for treating patients with cardiovascular diseases and defects. Such implantable devices are useful for replacing diseased, damaged, or congenitally malformed components of a patient's cardiovascular system.
- damaged or diseased heart valves have been replaced with chemically-fixed, bioprosthetic heart valves prepared from tissues of porcine or bovine origin.
- regions of damaged or diseased blood vessels may also be replaced with bioprosthetic vessels prepared from bovine tissues.
- the animal tissues used to form implantable devices are chemically cross-linked with agents, especially those animal tissue components that come into direct contact with the blood of a patient, and then chemically sterilized and preserved in a chemical solution.
- agents especially those animal tissue components that come into direct contact with the blood of a patient, and then chemically sterilized and preserved in a chemical solution.
- Such treatment is necessary to prevent rejection of the implanted bioprosthetic device by the recipient.
- Such treatment also stabilizes the protein components of the animal tissue, thus making them more resistant to degradation by proteolytic enzymes.
- a method for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject.
- One step of the method comprises preparing a substantially dehydrated bioprosthetic valve and providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends.
- the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member.
- the expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject.
- a method for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject.
- One step of the method comprises preparing a substantially dehydrated bioprosthetic valve and providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends.
- the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member.
- the expandable support member is next crimped into a compressed configuration and exposed to a re-hydrating fluid.
- the substantially dehydrated bioprosthetic valve is then placed at a desired location within the cardiovascular system of the subject.
- a method for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject.
- One step of the method comprises preparing a substantially dehydrated bioprosthetic valve and providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends.
- the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member.
- the substantially dehydrated bioprosthetic valve is next exposed to a re-hydrating fluid.
- the expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject.
- FIG. 1 is a flow diagram illustrating a method for implanting a valve having at least one leaflet within the cardiovascular system of the subject in accordance with the present invention
- FIG. 2 is a cross-sectional schematic view of a human heart
- FIG. 3 is a perspective view of a substantially dehydrated bioprosthetic valve securely attached to an expandable support member in an expanded configuration
- FIG. 4 is a perspective view showing a process for forming the valve shown in FIG. 3 ;
- FIG. 5A is a perspective view showing an alternative embodiment of the valve in FIG. 3 ;
- FIG. 5B is a perspective view showing another alternative embodiment of the valve in FIG. 5A ;
- FIG. 6 is a perspective view showing a process for collapsing the expandable support member shown in FIG. 3 into a compressed configuration
- FIG. 7 is a cross-sectional view showing a guidewire extending trans-septally through a human heart
- FIG. 8 is a cross-sectional view showing the guidewire extending through the mitral valve into the left ventricle
- FIG. 9 is a cross-sectional view showing a delivery catheter advanced over the guidewire.
- FIG. 10A is a perspective view showing the valve of FIG. 6 attached to the guidewire;
- FIG. 10B is a perspective view showing the valve of FIG. 10A loaded into the delivery catheter;
- FIG. 11 is a cross-sectional view showing the valve of FIG. 10B positioned at a distal end of the delivery catheter;
- FIG. 12 is a cross-sectional view of a magnified mitral valve showing the valve of FIG. 6 being delivered to the mitral valve;
- FIG. 13 is a cross-sectional view of a magnified mitral valve showing the valve of FIG. 3 securely positioned in place of the mitral valve;
- FIG. 14 is a flow diagram illustrating an alternative embodiment of the present invention.
- FIG. 15A is a perspective view showing the valve of FIG. 6 being exposed to a re-hydrating fluid
- FIG. 15B is a perspective view showing the valve of FIG. 15A immersed in the re-hydrating fluid
- FIG. 16 is a perspective view showing the valve of FIG. 5A contained in a delivery catheter and being delivered to a mitral valve via a port at the left ventricular apex;
- FIG. 17 is a perspective view showing the valve of FIG. 16 in an expanded configuration in place of the mitral valve
- FIG. 18 is a perspective view showing the valve of FIG. 5A contained in a delivery catheter and being delivered to a mitral valve via a port at the left atrial appendage;
- FIG. 19 is a perspective view showing the valve of FIG. 18 in an expanded configuration in place of the mitral valve
- FIG. 20 is a flow diagram illustrating another alternative embodiment of the present invention.
- FIG. 21 is a graph depicting the flow performance of a valve comprised of bovine pericardium constructed in accordance with the present invention.
- FIG. 22 is a graph comparing the flow performance of a valve and a control valve, each comprised of porcine pericardium.
- the control valve was dehydrated, crimped, sterilized, stored in a fluid-free container for 53 days, and then re-hydrated in water prior to testing;
- FIG. 23 is a graph comparing the flow performance of a valve and a control valve, each comprised of bovine pericardium.
- the control valve was dehydrated, crimped, sterilized, stored in a fluid-free container for 53 days, and then re-hydrated in water prior to testing;
- FIG. 24 is a graph depicting the flow performance of a control valve comprised of bovine pericardium.
- FIG. 25 is a graph comparing the flow performance of a valve and a control valve, each comprised of porcine pericardium.
- the control valve was dehydrated, crimped, sterilized, stored in a fluid-free container for 53 days, and then re-hydrated in water prior to testing.
- the present invention relates generally to a method for treating and improving the function of cardiovascular valves, and more particularly to a method for implanting a cardiovascular valve within the cardiovascular system of a subject.
- cardiovascular system refers to a bodily system consisting of the heart, blood vessels, and blood that circulates blood throughout the body, delivers nutrients and other essential materials to cells, and removes waste products.
- FIG. 1 illustrates a method 10 for implanting a valve 30 ( FIG. 3 ) having at least one valve leaflet 36 within the cardiovascular system of a subject, wherein the valve comprises a substantially dehydrated bioprosthetic valve 32 securely attached to an expandable support member 34 .
- the method 10 FIG.
- the present method 10 also avoids the problems associated with exposing manufacturing or operating room personnel to the fumes given off by aldehyde-containing solutions, in turn reducing the risk of damaging the valve 30 and the amount of time spent in the operating room preparing the valve for implantation.
- the right and left ventricles 56 and 58 pump oxygenated and deoxygenated blood, respectively, throughout the body, and the pocket-like semilunar pulmonary valve (not shown) and the aortic valve (not shown) prevent reflux into the ventricles.
- Atrial blood is pumped through the atrioventricular orifices, guarded by the tri-leaflet tricuspid valve 68 on the right side of the heart 50 and the bi-leaflet mitral valve 70 on the left side of the heart.
- the leaflets 72 of the mitral valve 70 are attached to the papillary muscles 74 in the right and left ventricles 56 and 58 by chordae tendineae 76 .
- the leaflets 78 of the tricuspid valve 68 are attached to the papillary muscles 74 in the right and left ventricles 56 and 58 by chordae tendineae 76 .
- tissue component 38 ( FIG. 4 ) is fixed by treating the tissue component with an aqueous solution comprising at least one non-volatile, biocompatible dimensional stabilizer at a concentration, temperature, and for a time sufficient to allow an equilibrium to be reached between the fluids in the interstices of the tissue component and the aqueous solution.
- tissue component refers to tissue that is dissected from an animal including, for example, muscular tissues, connective tissues, epithelial tissues, or combinations thereof, and tissues or tissue precursors that are formed in animal cell cultures.
- the tissue component 38 can include, but is not limited to, a heart valve (e.g., a bi- or tri-leaflet valve), peritoneum, pleura, submucosal tissue, dura mater and/or pericardium obtained from non-human animals, such as porcine, equine and/or bovine animals, in addition to human donors (e.g., cadaveric tissue).
- a heart valve e.g., a bi- or tri-leaflet valve
- peritoneum e.g., pleura, submucosal tissue, dura mater and/or pericardium obtained from non-human animals, such as porcine, equine and/or bovine animals, in addition to human donors (e.g., cadaveric tissue).
- Dimensional stabilizers include organic molecules that are hydrophilic and that comprise a plurality of carbon atoms attached to a plurality of hydroxyl groups.
- dimensional stabilizers include, but are not limited to, water soluble polyhydric alcohols such as glycerol, ethylene glycol, polyethylene glycols, propylene glycol, butylene glycol, sorbitol, mannitol, and pentaerythritol; water soluble carbohydrates such as ribose, maltose, sucrose, fructose, dextrose, dextran, cellulose, and methyl cellulose; pectin; derivatives of glycerol including, for example, glycerol bori-borate and glycerol borate akerite glycerin alternative; and water soluble gums.
- the tissue component 38 is contacted with the aqueous treatment solution for a time and at a temperature sufficient to permit the treatment solution to penetrate into the interstices of the tissue component and achieve an equilibrium between the treatment solution and the fluids in the interstices of the tissue component.
- the time needed to achieve such equilibrium is directly related to the thickness of the tissue component 38 and to the concentration of the dimensional stabilizer in the solution. Additionally, the time needed to achieve equilibrium is inversely related to the ratio between the volumes of the treatment solution and the tissue component 38 to the rate of mixing of the treatment solution.
- the substantially dehydrated bioprosthetic valve 32 is formed. As illustrated in FIG. 4 , the tissue component 38 is first securely attached to a root component 40 .
- the root component 40 provides both structural support and a substrate for attachment of the tissue component 38 .
- the root component 40 may be made of a scaffolding material, such as a harvested aortic root, for example, or any other suitable scaffolding material, such as biological tissue (e.g., pericardium, peritoneal tissue, submucosal tissue, dura mater, and the like), polytetrafluoroethylene (ePTFE), polyester or polyurethane.
- the root component 40 may be fixed in an identical or similar manner as the tissue component 38 .
- the root component 40 is securely attached to the tissue component 38 using, for example, sutures or any other known attachment means (e.g., pins, clips, staples, adhesives, and the like). It will be appreciated that the tissue component 38 may be treated with the aqueous treatment solution prior to the time it is fashioned into the substantially dehydrated bioprosthetic valve 32 , after it is fashioned into the substantially dehydrated bioprosthetic valve, or at both stages in the manufacture of the substantially dehydrated bioprosthetic valve.
- an expandable support member 34 is then provided at 14 .
- the expandable support member 34 comprises oppositely disposed first and second ends 42 and 44 and a main body portion 46 extending between the ends.
- the expandable support member 34 has a known stent configuration that allows it to be expanded and compressed ( FIG. 6 ).
- the flexible and expandable properties of the expandable support member 34 facilitate percutaneous delivery of the valve 30 .
- the expandable support member 34 may be made from any suitable medical grade metal or plastic, including shape memory materials such as Nitinol, stainless steel, and/or titanium. Additionally, at least a portion of the expandable support member 34 may be made from a bioabsorbable material including, for example, magnesium alloy, dendrimers, biopolymers such as thermoplastic starch, polyalctides, cellulose, and aliphatic aromatic copolyesters.
- the expandable support member 34 is generally annular in shape and may be comprised of a continuous series of W-shaped segments 48 collectively forming a mesh-like configuration. It is contemplated, however, that other geometries may be used. As shown in FIG. 3 , the W-shaped segments 48 comprising the first and second ends 42 and 44 extend radially from the main body portion 46 of the expandable support member 34 . As described in more detail below, the radial configuration of the first and second ends 42 and 44 facilitates implantation of the valve 30 . It should be appreciated that the substantially dehydrated bioprosthetic valve 32 may be formed (i.e., treated) after attachment to the expandable support member 34 .
- valve 30 may include other bioprosthetic valves known in the art.
- the valve 30 may be constructed in an identical or similar fashion as the bioprosthetic valves illustrated in FIGS. 5A and 5B and disclosed in U.S. Patent Pub. Nos. 2006/0195183 A1 and 2006/0259135 A1, the entireties of which are hereby incorporated by reference.
- a valve 30 ′ can comprise an expandable support member 34 ′ having oppositely disposed first and second ends 42 ′ and 44 ′ and a main body portion 46 ′ extending between the ends.
- the first and second ends 42 ′ and 44 ′ of the expandable support member 34 ′ can respectively include a plurality of upper and lower wing members 94 and 96 that extend from the main body portion 46 ′ and are spaced circumferentially apart about the main body portion.
- Each of the upper and lower wing members 94 and 96 can include at least one attachment mechanism 98 .
- the at least one attachment mechanism 98 can comprise a barb 100 or hook capable of embedding into cardiovascular tissue.
- each of the upper and lower wing members 94 and 96 can respectively include first and second magnetic components 102 and 104 as shown in FIG. 5B .
- the first and second magnetic components 102 and 104 may be magnetically attracted to one another so that, when the valve 30 ′ is placed in the annulus 90 ( FIG. 12 ) of a mitral valve 70 , for example, the upper and lower wing members 94 and 96 ( FIGS. 5A and 5B ) are pulled toward one another to secure the valve in the mitral annulus.
- the second end 44 ′ of the expandable support member 34 ′ may also include at least two strut members 106 that are spaced apart from each other.
- a tissue component 38 ′ such as a substantially dehydrated bioprosthetic valve 32 ′, may be secured within the main body portion 46 ′ of the expandable support member 34 ′ as shown in FIGS. 5A and 5B .
- the substantially dehydrated bioprosthetic valve 32 ′ can comprise a valve having at least two valve leaflets that are coaptable to permit unidirectional blood flow.
- the tissue component 38 ′ may alternatively have a tri-leaflet configuration (not shown).
- Each of the at least two valve leaflets may be joined together at least two commissural sections 112 that are spaced apart from each other.
- Each of the at least two commissural sections 112 may be attached to a respective one of the strut members 106 to prevent prolapse of the valve leaflets.
- the expandable support member 34 may further include a layer 80 of biocompatible material covering at least a portion of the expandable support member 34 .
- the layer 80 of biocompatible material may be synthetic, such as polyester (e.g., Dacron®) (Invista, Wichita, Kans.), woven velour, polyurethane, PTFE, ePTFE, Gore-Tex® (W.L. Gore & Associates, Flagstaff, Ariz.), or heparin-coated fabric.
- the layer 80 may be a biological material such as bovine, equine, and/or porcine pericardium, peritoneal tissue, pleura, submucosal tissue, dura mater, an allograft, a homograft, a patient graft, or a cell-seeded tissue.
- a biological material such as bovine, equine, and/or porcine pericardium, peritoneal tissue, pleura, submucosal tissue, dura mater, an allograft, a homograft, a patient graft, or a cell-seeded tissue.
- the layer 80 can cover either the inside surface of the expandable support member 34 , the outside surface of the expandable support member, or can be wrapped around both the inside and outside surfaces.
- the layer 80 may be attached around the entire circumference of the expandable support member 34 or, alternatively, may be attached in pieces or interrupted sections to allow the expandable support member to more easily expand and contract. As shown in FIG. 3 , for example, only the main body portion 46 of the expandable support member 34 may be covered with the layer 80 of biocompatible material. The entire expandable support member 34 may be entirely covered with the layer 80 of biocompatible material or, alternatively, not covered at all.
- the expandable support member 34 may include at least one radiographically opaque marking (not shown).
- the radiographically opaque marking may be located at any other portion of the expandable support member 34 .
- the radiographically opaque marking can be any one or combination of materials or devices with significant opacity. Examples of such radiographically opaque markings include, but are not limited to, a steel mandrel sufficiently thick to be visible on fluoroscopy, a tantalumlpolyurethane tip, a gold-plated tip, bands of platinum, stainless steel or gold, soldered spots of gold, and polymeric materials with a radiographically opaque filler such as barium sulfate.
- the expandable support member 34 may also include at least one therapeutic agent for eluting into the cardiovascular tissue and/or blood stream.
- the therapeutic agent may be capable of preventing a variety of pathological conditions including, but not limited to, hypertension, hypotension, arrhythmias, thrombosis, stenosis and inflammation.
- the therapeutic agent may include at least one of an anti-arrhythmic agent, an anti-hypertensive, an anti-hypotensive agent, an anticoagulant, an antioxidant, a fibrinolytic, a steroid, an anti-apoptotic agent, an anti-mineralization agent, an anti-calcification agent, and/or an anti-inflammatory agent.
- the therapeutic agent may be capable of treating or preventing other diseases or disease processes such as microbial infections and heart failure.
- the therapeutic agent may include an inotropic agent, a chronotropic agent, an anti-microbial agent, and/or a biological agent such as a cell, peptide, or nucleic acid.
- the therapeutic agent can be linked to a surface of the expandable support member 34 , embedded and released from within polymer materials, such as a polymer matrix, or surrounded by and released through a carrier.
- the expandable support member 34 is crimped into a compressed configuration at 18 ( FIG. 6 ).
- the expandable support member 34 may be crimped using tactile means, for example, or by any other method, including various mechanical-based devices, such as the device 116 illustrated in FIG. 6 , known in the art. Crimping the expandable support member 34 into a compressed configuration facilitates percutaneous delivery of the valve 30 at 132 .
- the crimped valve 30 is then stored in an environment (not shown) essentially free of liquid for later processing or implantation. It will be appreciated that the valve 30 may also be stored in the expanded configuration.
- An environment, container (not shown), or package (not shown) that is “essentially free of liquid” as described herein refers to a non-fluid environment in which the presence of water or other liquids is limited to the content of such liquids in the ambient air (as more precisely defined by the relative humidity), and the content of liquid contained within the substantially dehydrated bioprosthetic valve 32 disposed within a container or package.
- the valve 30 may be placed into the chamber of a microorganism-resistant container. After the valve 30 is placed in the chamber at 132 , the chamber is sealed and sterilized at 134 by, for example, exposure to ionizing radiation or a sterilizing gas (e.g., ethylene oxide).
- a sterilizing gas e.g., ethylene oxide
- the valve 30 may be placed in a delivery catheter 86 and the delivery catheter then stored in a container essentially free of liquid.
- the valve 30 is placed at a desired location within the cardiovascular system of a subject. As illustrated in FIGS. 7-13 , for example, the valve 30 may be placed within the cardiovascular system of a subject to replace a diseased mitral valve 70 . It should be appreciated, however, that the valve 30 may be implanted at any desired location within the cardiovascular system of subject, including, for example, in place of a tricuspid valve 68 , an aortic valve, a pulmonary valve, a pulmonary artery (not shown) or vein 66 , a venous valve, an inferior vena cava 64 , a superior vena cava 62 , or any other peripheral artery or venous valve.
- the dimensions of the diseased mitral valve 70 are determined using known imaging techniques including, for example, magnetic resonance imaging (MRI), fluoroscopy, computed tomography (CT), angiography, ultrasound, and combinations thereof. After determining the dimensions of the diseased mitral valve 70 , an appropriately-sized valve 30 having dimensions that correspond to the dimensions of the diseased mitral valve is selected.
- MRI magnetic resonance imaging
- CT computed tomography
- ultrasound ultrasound
- a guidewire 82 is inserted into the vasculature of the subject via a femoral vein (not shown) or jugular vein (not shown) and, under image guidance (e.g., fluoroscopy, ultrasound, MRI, CT, or combinations thereof), respectively steered through the vasculature of the subject into the inferior vena cava 64 or superior vena cava 62 .
- the guidewire 82 is then passed across the right atrium 52 so that the distal end 84 of the guidewire pierces the interatrial septum 60 as shown in FIG. 7 .
- the guidewire 82 is extended across the left atrium 54 and then downward through the diseased mitral valve 70 so that the distal end 84 of the guidewire is securely positioned in the left ventricle 58 ( FIG. 8 ).
- a delivery catheter 86 is passed over the guidewire as shown in FIG. 9 .
- the delivery catheter 86 may be comprised of a flexible, resiliently yieldable material such as silicone, PTFE, ePTFE, plastic polymer, or the like.
- the appropriately-sized valve 30 is removed from the sterile container, attached to the proximal end 114 of the guidewire 82 ( FIG. 10A ), and loaded into the delivery catheter ( FIG. 10B ). If needed, the valve 30 may be rinsed with a sterile solution or liquid, such as sterile saline or water, just prior to loading the valve into the delivery catheter 86 .
- a positioning wire (not shown) or other similar device useful for advancing the valve 30 over the guidewire 82 is then attached to the valve. An axial force is then applied to the positioning wire so that the valve 30 is passed over the guidewire 82 and positioned at the distal end 88 of the delivery catheter 86 ( FIG. 11 ).
- the valve 30 Upon reaching the distal end 88 of the delivery catheter 86 , the valve 30 is progressively freed from the delivery catheter and positioned in the mitral annulus 90 as shown in FIG. 12 . As the valve 30 is progressively freed from the delivery catheter 86 , the position of the valve in the left atrium 54 can be monitored, controlled, and/or quality assured by imaging systems of various kinds. For example, X-ray machines, fluoroscopic machines, ultrasound, CT, MRI, positron emission tomography (PET), and other imaging devices may be used.
- imaging systems of various kinds. For example, X-ray machines, fluoroscopic machines, ultrasound, CT, MRI, positron emission tomography (PET), and other imaging devices may be used.
- the expandable support member 34 obtains an expanded configuration at 22 as the expandable support member is progressively freed from the delivery catheter 86 .
- the first end 42 of the expandable support member 34 engages the superior aspect 92 of the mitral valve annulus 90
- the second end 44 displaces the mitral leaflets 72 so that the leaflets are pinned back against the annulus of the mitral valve.
- the interstices of the substantially dehydrated bioprosthetic valve are re-hydrated, causing the substantially dehydrated bioprosthetic valve to obtain its original (or substantially original) properties and assume normal (or substantially normal) blood flow performance ( FIGS. 21-25 ). Because the valve 30 has been prepared and conditioned prior to delivery, the time needed to prepare the valve for delivery in the operating room is significantly reduced. Additionally, comparable devices prepared in the operating room do not provide such a consistent quality of manufacture as does the valve 30 of the present invention.
- FIG. 14 Another embodiment of the present invention is illustrated in FIG. 14 .
- a method 10 a is provided for implanting a valve 30 ′ having at least one valve leaflet 36 ′ within the cardiovascular system of a subject.
- the method 10 a is identical to the method 10 illustrated in FIG. 1 , except where as described below.
- a substantially dehydrated bioprosthetic valve 32 ′ may be prepared at 12 a and securely attached at 16 a to an expandable support member 34 ′ to form the valve 30 ′ shown in FIG. 5A (as described above).
- the expandable support member 34 ′ may then be crimped into a compressed configuration at 18 a , stored at 132 a , and then sterilized at 134 a .
- the substantially dehydrated bioprosthetic valve 32 ′ may be exposed to a re-hydrating fluid at 118 ( FIG. 15A ).
- the re-hydrating fluid can comprise saline or sterile water, for example, and may be contained in a suitable container 120 .
- the valve 30 ′ may be immersed in the re-hydrating fluid for a time appropriate so that the substantially dehydrated bioprosthetic valve 32 ′ is re-hydrated and obtains (or substantially obtains) its original properties.
- the valve 30 ′ may be loaded into a delivery catheter 86 as shown in FIG. 16 .
- the valve 30 ′ may be operably disposed about an inflatable balloon 122 which may be selectively inflated to expand the valve. It should be appreciated, however, that an inflatable balloon 122 may not be included where the valve 30 ′ is self-expanding.
- access to a desired location within the cardiovascular system of a subject may then be obtained.
- access to a diseased mitral valve 70 of a subject may be obtained via a minimally invasive, open surgical approach whereby a port 124 is created at the left ventricular apex 126 .
- the delivery catheter 86 may be inserted through the port and the distal end 88 of the catheter positioned in the diseased mitral valve 70 as shown in FIG. 16 .
- the valve 30 ′ may next be advanced to the distal end 88 of the delivery catheter 86 .
- the delivery catheter 86 may then be progressively withdrawn so that the valve 30 ′ is positioned in the diseased mitral valve 70 .
- the valve 30 ′ may be expanded by inflating the inflatable balloon 122 as shown in FIG. 17 .
- the barbs 100 of the upper and lower wing members 94 and 96 respectively engage the superior and inferior aspects 92 and 128 of the mitral valve annulus 90 .
- the lower wing members 96 pin the mitral leaflets 72 against the annular wall and secure the valve 30 ′ in place of the diseased mitral valve 70 .
- percutaneous access to a desired location within the cardiovascular system of a subject may be obtained via a left atrial appendage 130 .
- a port 124 or puncture may be made at the left atrial appendage 130 so that a guidewire 82 may be inserted into the port and then threaded through the left atrium 54 , across the diseased mitral valve 70 , and into the left ventricle 58 .
- a delivery catheter 86 may be advanced over the guidewire 82 so that the distal end 88 of the catheter is positioned in the diseased mitral valve 70 ( FIG. 18 ).
- access to other desired locations within the cardiovascular system of a subject may also be obtained using known approaches.
- access to the tricuspid valve 68 may be obtained via right atrial appendage (not shown).
- access may be obtained through the ascending aorta (not shown) or left ventricular apex 126 ( FIG. 16 ).
- access may be obtained via the pulmonary artery (not shown), the right ventricle 56 , and/or right ventricular outflow track.
- the valve 30 ′ may be loaded into the delivery catheter 86 as described above.
- the valve 30 ′ may then be advanced to the distal end 88 of the delivery catheter 86 as shown in FIG. 18 , and then progressively withdrawn from the subject.
- the inflatable balloon 122 may next be inflated to expand the valve 30 ′ ( FIG. 19 ). Expanding the valve 30 ′ allows the barbs 100 of the upper and lower wing members 94 and 96 to respectively engage the superior and inferior aspects 92 and 128 of the diseased mitral valve 70 . In doing so, the lower wing members 96 pin the mitral leaflets 72 against the annular wall and secure the valve 30 ′ in place of the diseased mitral valve 70 .
- FIG. 20 Another embodiment of the present invention is illustrated in FIG. 20 .
- a method 10 b is provided for implanting a valve 30 having at least one valve leaflet 36 within the cardiovascular system of a subject.
- the method 10 b is identical to the method 10 illustrated in FIG. 1 , except where as described below.
- a substantially dehydrated bioprosthetic valve 32 may be prepared at 12 b and securely attached to an expandable support member 34 at 16 b .
- the substantially dehydrated bioprosthetic valve may be attached to an expandable support member 34 at 16 b to form a valve 30 , and then exposed to a re-hydrating fluid at 118 .
- the valve 30 may be immersed in the re-hydrating fluid for a time appropriate so that the substantially dehydrated bioprosthetic valve 32 is re-hydrated and obtains (or substantially obtains) its original properties.
- the valve 30 may next be loaded into a delivery catheter 86 as described above. Access to a desired location within the cardiovascular system of a subject may then be obtained. As described above, for example, access to a femoral vein may be obtained so that the valve 30 may be implanted in place of a diseased mitral valve 70 . After obtaining access to the cardiovascular system of the subject, the valve 30 may be appropriately placed and expanded at 20 b and 22 b , respectively (as described above). Because the substantially dehydrated bioprosthetic valve 32 is re-hydrated prior to implantation, the substantially dehydrated bioprosthetic valve can function normally immediately upon introduction to the cardiovascular system of the subject.
- valve 30 may be rinsed prior to implantation.
- the delivery catheter may be rinsed or flushed with a sterile fluid, such as sterile saline or water, before insertion into a subject.
- a sterile fluid such as sterile saline or water
- the valve 30 may be rinsed while in an expanded configuration in a suitable container 120 , for example, crimped into the compressed configuration, and delivered to a subject as described above.
- the substantially dehydrated bioprosthetic valve 32 may be exposed to a re-hydrating or rinsing solution while the valve 30 is disposed within a delivery catheter 86 prior to delivery.
- improvements, changes and modifications within the skill of the art are intended to be covered by the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/016,168 US8105375B2 (en) | 2007-01-19 | 2008-01-17 | Method for implanting a cardiovascular valve |
US13/336,974 US20120095551A1 (en) | 2007-01-19 | 2011-12-23 | Method for implanting a cardiovascular valve |
US13/868,892 US9610160B2 (en) | 2007-01-19 | 2013-04-23 | Method for implanting a cardiovascular valve |
US15/478,210 US11547560B2 (en) | 2007-01-19 | 2017-04-03 | Implantable cardiovascular valve |
US18/078,769 US20230277315A1 (en) | 2007-01-19 | 2022-12-09 | Method for implanting a cardiovascular valve |
US18/536,798 US20240099840A1 (en) | 2007-01-19 | 2023-12-12 | Method for implanting a cardiovascular valve |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88124407P | 2007-01-19 | 2007-01-19 | |
US12/016,168 US8105375B2 (en) | 2007-01-19 | 2008-01-17 | Method for implanting a cardiovascular valve |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,974 Continuation US20120095551A1 (en) | 2007-01-19 | 2011-12-23 | Method for implanting a cardiovascular valve |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080177381A1 US20080177381A1 (en) | 2008-07-24 |
US8105375B2 true US8105375B2 (en) | 2012-01-31 |
Family
ID=39321510
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/016,168 Active 2030-05-03 US8105375B2 (en) | 2007-01-19 | 2008-01-17 | Method for implanting a cardiovascular valve |
US13/336,974 Abandoned US20120095551A1 (en) | 2007-01-19 | 2011-12-23 | Method for implanting a cardiovascular valve |
US13/868,892 Active US9610160B2 (en) | 2007-01-19 | 2013-04-23 | Method for implanting a cardiovascular valve |
US15/478,210 Active 2028-05-12 US11547560B2 (en) | 2007-01-19 | 2017-04-03 | Implantable cardiovascular valve |
US18/078,769 Pending US20230277315A1 (en) | 2007-01-19 | 2022-12-09 | Method for implanting a cardiovascular valve |
US18/536,798 Pending US20240099840A1 (en) | 2007-01-19 | 2023-12-12 | Method for implanting a cardiovascular valve |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,974 Abandoned US20120095551A1 (en) | 2007-01-19 | 2011-12-23 | Method for implanting a cardiovascular valve |
US13/868,892 Active US9610160B2 (en) | 2007-01-19 | 2013-04-23 | Method for implanting a cardiovascular valve |
US15/478,210 Active 2028-05-12 US11547560B2 (en) | 2007-01-19 | 2017-04-03 | Implantable cardiovascular valve |
US18/078,769 Pending US20230277315A1 (en) | 2007-01-19 | 2022-12-09 | Method for implanting a cardiovascular valve |
US18/536,798 Pending US20240099840A1 (en) | 2007-01-19 | 2023-12-12 | Method for implanting a cardiovascular valve |
Country Status (2)
Country | Link |
---|---|
US (6) | US8105375B2 (fr) |
WO (1) | WO2008089365A2 (fr) |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249917A1 (en) * | 2009-03-30 | 2010-09-30 | Ji Zhang | Methods for Delivery of a Sutureless Pulmonary or Mitral Valve |
US20130253643A1 (en) * | 2012-03-23 | 2013-09-26 | Sorin Group Italia S.R.L. | Collapsible valve prosthesis |
US8790398B2 (en) | 2002-01-04 | 2014-07-29 | Colibri Heart Valve Llc | Percutaneously implantable replacement heart valve device and method of making same |
WO2015031124A1 (fr) * | 2013-08-29 | 2015-03-05 | St. Jude Medical, Cardiology Division, Inc. | Valve de transcathéter à tissu lyophilisé |
US9029418B2 (en) | 2007-12-21 | 2015-05-12 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US9119738B2 (en) | 2010-06-28 | 2015-09-01 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
EP2926840A1 (fr) | 2014-04-02 | 2015-10-07 | Biotronik AG | Procédé de traitement de tissu biologique pour une utilisation à sec dans un implant |
US9186249B2 (en) | 2012-08-10 | 2015-11-17 | Sorin Group Italia S.R.L. | Valve prosthesis and kit |
US20150351904A1 (en) * | 2014-06-06 | 2015-12-10 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US9333073B2 (en) | 2009-04-15 | 2016-05-10 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery method |
US9339377B2 (en) | 2008-09-29 | 2016-05-17 | Edwards Lifesciences Cardiaq Llc | Body cavity prosthesis |
US9345573B2 (en) * | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9498317B2 (en) | 2010-12-16 | 2016-11-22 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US9597183B2 (en) | 2008-10-01 | 2017-03-21 | Edwards Lifesciences Cardiaq Llc | Delivery system for vascular implant |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
US9713529B2 (en) | 2011-04-28 | 2017-07-25 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9737400B2 (en) | 2010-12-14 | 2017-08-22 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
US9770329B2 (en) | 2010-05-05 | 2017-09-26 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US9867700B2 (en) | 2013-05-20 | 2018-01-16 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US10143550B2 (en) | 2013-08-08 | 2018-12-04 | Sorin Group Italia S.R.L. | Heart valve prosthesis |
US10245141B2 (en) | 2014-05-14 | 2019-04-02 | Sorin Group Italia S.R.L. | Implant device and implantation kit |
US10368988B2 (en) | 2016-11-09 | 2019-08-06 | Medtronic Vascular, Inc. | Valve delivery system having an integral displacement component for managing chordae tendineae in situ and methods of use thereof |
US10449044B2 (en) | 2016-06-02 | 2019-10-22 | Medtronic Vascular, Inc. | Transcatheter valve delivery system with septum hole closure tip assembly |
US10493248B2 (en) | 2016-11-09 | 2019-12-03 | Medtronic Vascular, Inc. | Chordae tendineae management devices for use with a valve prosthesis delivery system and methods of use thereof |
US10507104B2 (en) | 2013-03-14 | 2019-12-17 | Suzhou Jiecheng Medical Technology Co., Ltd. | Sutureless valve prosthesis delivery device and methods of use thereof |
US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
US10716668B2 (en) | 2017-04-05 | 2020-07-21 | Medtronic, Inc. | Delivery system with anchoring nosecone and method of delivery |
US10806574B2 (en) | 2017-11-20 | 2020-10-20 | Medtronic Vascular, Inc. | Delivery systems having a temporary valve and methods of use |
US10925728B2 (en) | 2018-02-22 | 2021-02-23 | Medtronic Vascular, Inc. | Prosthetic heart valve delivery systems and methods |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
US11071846B2 (en) | 2017-09-14 | 2021-07-27 | Medtronic Vascular, Inc. | Deflection catheter for aiding in bending of a catheter |
US11083577B2 (en) | 2018-01-07 | 2021-08-10 | Jc Medical, Inc. | Heart valve prosthesis |
US11135060B2 (en) | 2017-08-24 | 2021-10-05 | Medtronic Vascular, Inc. | Transseptal delivery systems having a deflecting segment and methods of use |
WO2022090420A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé pour la production de tissus réticulés et éventuellement façonnés avec ajustement sélectif de l'épaisseur, de la forme et/ou de la flexibilité |
WO2022090419A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de traitement de tissu non réticulé |
WO2022090417A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de liaison/jonction sans couture de tissus comprenant des groupes réticulables |
WO2022090418A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de mise en forme tridimensionnelle d'un tissu ou d'un composant de tissu |
US11395726B2 (en) | 2017-09-11 | 2022-07-26 | Incubar Llc | Conduit vascular implant sealing device for reducing endoleaks |
US11504231B2 (en) | 2018-05-23 | 2022-11-22 | Corcym S.R.L. | Cardiac valve prosthesis |
US11517428B2 (en) | 2018-11-01 | 2022-12-06 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
US11590261B2 (en) | 2014-04-02 | 2023-02-28 | Biotronik Ag | Method for the preparation of biological tissue for dry use in an implant |
US11612482B2 (en) | 2019-03-06 | 2023-03-28 | Medtronic, Inc. | Trans-septal delivery system and methods of use |
WO2023208607A1 (fr) | 2022-04-29 | 2023-11-02 | Biotronik Ag | Procédé de production de tissu biologique |
US11832829B2 (en) | 2017-04-20 | 2023-12-05 | Medtronic, Inc. | Stabilization of a transseptal delivery device |
US12023417B2 (en) | 2018-01-23 | 2024-07-02 | Edwards Lifesciences Corporation | Method for pre-stretching implantable biocompatible materials, and materials, and devices produced thereby |
US12023416B2 (en) | 2017-05-31 | 2024-07-02 | Edwards Lifesciences Corporation | Collagen fibers and articles formed therefrom |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6488689B1 (en) | 1999-05-20 | 2002-12-03 | Aaron V. Kaplan | Methods and apparatus for transpericardial left atrial appendage closure |
CA3075142C (fr) | 2001-10-04 | 2022-05-17 | Neovasc Medical Ltd. | Implant reducteur de flux |
IL158960A0 (en) | 2003-11-19 | 2004-05-12 | Neovasc Medical Ltd | Vascular implant |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US20050137687A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical | Heart valve anchor and method |
US9526609B2 (en) | 2003-12-23 | 2016-12-27 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US8603160B2 (en) | 2003-12-23 | 2013-12-10 | Sadra Medical, Inc. | Method of using a retrievable heart valve anchor with a sheath |
US7959666B2 (en) * | 2003-12-23 | 2011-06-14 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a heart valve |
ITTO20040135A1 (it) | 2004-03-03 | 2004-06-03 | Sorin Biomedica Cardio Spa | Protesi valvolare cardiaca |
DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
ITTO20050074A1 (it) | 2005-02-10 | 2006-08-11 | Sorin Biomedica Cardio Srl | Protesi valvola cardiaca |
EP3167847B1 (fr) | 2005-11-10 | 2020-10-14 | Edwards Lifesciences CardiAQ LLC | Prothèse cardiaque |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
WO2008013915A2 (fr) * | 2006-07-28 | 2008-01-31 | Arshad Quadri | Prothèse à valve percutanée et système et procédé pour implanter une telle prothèse |
US20110257723A1 (en) | 2006-11-07 | 2011-10-20 | Dc Devices, Inc. | Devices and methods for coronary sinus pressure relief |
US9232997B2 (en) | 2006-11-07 | 2016-01-12 | Corvia Medical, Inc. | Devices and methods for retrievable intra-atrial implants |
US10413284B2 (en) | 2006-11-07 | 2019-09-17 | Corvia Medical, Inc. | Atrial pressure regulation with control, sensing, monitoring and therapy delivery |
AU2007317191B2 (en) | 2006-11-07 | 2014-02-20 | Corvia Medical, Inc. | Devices and methods for the treatment of heart failure |
US8105375B2 (en) * | 2007-01-19 | 2012-01-31 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
WO2009024859A2 (fr) | 2007-08-21 | 2009-02-26 | Symetis Sa | Endoprothèses valvulaires pour un remplacement de valvule et procédés associés et systèmes pour une chirurgie |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US8006535B2 (en) | 2007-07-12 | 2011-08-30 | Sorin Biomedica Cardio S.R.L. | Expandable prosthetic valve crimping device |
EP2014257B1 (fr) * | 2007-07-12 | 2010-09-08 | Sorin Biomedica Cardio S.R.L. | Dispositif de gaufrage de valve prosthétique extensible |
DE102007043830A1 (de) | 2007-09-13 | 2009-04-02 | Lozonschi, Lucian, Madison | Herzklappenstent |
US9848981B2 (en) | 2007-10-12 | 2017-12-26 | Mayo Foundation For Medical Education And Research | Expandable valve prosthesis with sealing mechanism |
EP2205183B1 (fr) | 2007-10-25 | 2018-11-28 | Symetis SA | Un systeme pour remplacer une valve cardiaque |
AU2009219415B2 (en) † | 2008-02-25 | 2013-01-17 | Medtronic Vascular Inc. | Infundibular reducer devices |
BR112012021347A2 (pt) | 2008-02-26 | 2019-09-24 | Jenavalve Tecnology Inc | stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
US8728153B2 (en) * | 2008-05-14 | 2014-05-20 | Onset Medical Corporation | Expandable transapical sheath and method of use |
US8668668B2 (en) * | 2008-05-14 | 2014-03-11 | Onset Medical Corporation | Expandable iliac sheath and method of use |
EP4215162A1 (fr) | 2008-07-15 | 2023-07-26 | St. Jude Medical, LLC | Conceptions de manchon de valvule cardiaque prothétique repliable et redéployable et applications technologiques complémentaires |
US8834563B2 (en) | 2008-12-23 | 2014-09-16 | Sorin Group Italia S.R.L. | Expandable prosthetic valve having anchoring appendages |
US8715207B2 (en) | 2009-03-19 | 2014-05-06 | Sorin Group Italia S.R.L. | Universal valve annulus sizing device |
US20100262043A1 (en) | 2009-03-26 | 2010-10-14 | Sorin Group Usa, Inc. | Annuloplasty sizers for minimally invasive procedures |
EP2429455B8 (fr) * | 2009-04-29 | 2021-12-15 | Edwards Lifesciences Corporation | Appareil pour remplacer une valvule cardiaque malade |
US8075611B2 (en) | 2009-06-02 | 2011-12-13 | Medtronic, Inc. | Stented prosthetic heart valves |
US9757107B2 (en) | 2009-09-04 | 2017-09-12 | Corvia Medical, Inc. | Methods and devices for intra-atrial shunts having adjustable sizes |
US8652203B2 (en) | 2010-09-23 | 2014-02-18 | Cardiaq Valve Technologies, Inc. | Replacement heart valves, delivery devices and methods |
US9730790B2 (en) * | 2009-09-29 | 2017-08-15 | Edwards Lifesciences Cardiaq Llc | Replacement valve and method |
BR112012010321B8 (pt) * | 2009-11-02 | 2021-06-22 | Symetis Sa | válvula de substituição para uso em um corpo humano |
CA3050297A1 (fr) | 2009-11-05 | 2011-05-12 | The Trustees Of The University Of Pennsylvania | Prothese de valve |
US8449599B2 (en) | 2009-12-04 | 2013-05-28 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
CA2783282C (fr) | 2009-12-08 | 2018-04-03 | Avalon Medical Ltd. | Dispositif et systeme de remplacement de valvule mitrale transcatheter |
US8869982B2 (en) | 2009-12-18 | 2014-10-28 | Edwards Lifesciences Corporation | Prosthetic heart valve packaging and deployment system |
US9358109B2 (en) * | 2010-01-13 | 2016-06-07 | Vinay Badhwar | Transcorporeal delivery system and method |
CN102905626A (zh) * | 2010-01-29 | 2013-01-30 | Dc设备公司 | 用于治疗心脏衰竭的装置和*** |
CA2785041A1 (fr) | 2010-01-29 | 2011-08-04 | Dc Devices, Inc. | Dispositifs et procedes de reduction de la pression veineuse |
EP3028672A1 (fr) * | 2010-03-01 | 2016-06-08 | Colibri Heart Valve LLC | Valvule cardiaque pouvant être posée par voie percutanée et procédés associés |
US8679404B2 (en) | 2010-03-05 | 2014-03-25 | Edwards Lifesciences Corporation | Dry prosthetic heart valve packaging system |
JP6085553B2 (ja) | 2010-04-13 | 2017-02-22 | センターハート・インコーポレイテッドSentreHEART, Inc. | 心臓にデバイスをアクセスおよび送達するためのデバイスおよび方法 |
IT1400327B1 (it) | 2010-05-21 | 2013-05-24 | Sorin Biomedica Cardio Srl | Dispositivo di supporto per protesi valvolari e corrispondente corredo. |
US9744031B2 (en) | 2010-05-25 | 2017-08-29 | Jenavalve Technology, Inc. | Prosthetic heart valve and endoprosthesis comprising a prosthetic heart valve and a stent |
AU2011271007A1 (en) | 2010-06-21 | 2013-01-31 | Cardiaq Valve Technologies, Inc. | Replacement heart valve |
CA2804771C (fr) | 2010-07-09 | 2018-02-20 | Highlife Sas | Prothese de valve atrio-ventriculaire transcatheter |
US8518107B2 (en) | 2010-08-04 | 2013-08-27 | Valcare, Inc. | Percutaneous transcatheter repair of heart valves |
US9011527B2 (en) * | 2010-09-20 | 2015-04-21 | St. Jude Medical, Cardiology Division, Inc. | Valve leaflet attachment in collapsible prosthetic valves |
EP2673038B1 (fr) | 2011-02-10 | 2017-07-19 | Corvia Medical, Inc. | Appareil pour créer et maintenir une ouverture d'évacuation de pression intra-auriculaire |
EP2486893B1 (fr) | 2011-02-14 | 2017-07-05 | Sorin Group Italia S.r.l. | Dispositif d'ancrage sans suture pour prothèses valvulaires cardiaques |
EP2486894B1 (fr) | 2011-02-14 | 2021-06-09 | Sorin Group Italia S.r.l. | Dispositif d'ancrage sans suture pour prothèses valvulaires cardiaques |
EP4119095A1 (fr) | 2011-03-21 | 2023-01-18 | Cephea Valve Technologies, Inc. | Appareil à soupape basé sur disque |
US9402721B2 (en) * | 2011-06-01 | 2016-08-02 | Valcare, Inc. | Percutaneous transcatheter repair of heart valves via trans-apical access |
AU2012282660B2 (en) | 2011-07-11 | 2017-07-27 | The Children's Hospital Of Philadelphia | Oxidation resistant bioprosthetic tissues and preparation thereof |
CA3040390C (fr) | 2011-08-11 | 2022-03-15 | Tendyne Holdings, Inc. | Ameliorations apportees a des valves prothetiques et inventions associees |
EP2747709A4 (fr) * | 2011-09-09 | 2015-04-15 | Univ Emory | Systèmes, dispositifs et procédés de réparation de lésions de valvule cardiaque |
US9662206B2 (en) | 2011-09-12 | 2017-05-30 | Highlife Sas | Transcatheter valve prosthesis |
US9387075B2 (en) | 2011-09-12 | 2016-07-12 | Highlife Sas | Transcatheter valve prosthesis |
US9358108B2 (en) | 2011-09-12 | 2016-06-07 | Highlife Sas | Transcatheter valve prosthesis |
US9827092B2 (en) | 2011-12-16 | 2017-11-28 | Tendyne Holdings, Inc. | Tethers for prosthetic mitral valve |
US9205236B2 (en) | 2011-12-22 | 2015-12-08 | Corvia Medical, Inc. | Methods, systems, and devices for resizable intra-atrial shunts |
EP3281608B1 (fr) * | 2012-02-10 | 2020-09-16 | CVDevices, LLC | Mediyinprodukt mit rahmen und viszeralen pleura |
US9180008B2 (en) | 2012-02-29 | 2015-11-10 | Valcare, Inc. | Methods, devices, and systems for percutaneously anchoring annuloplasty rings |
US9839519B2 (en) | 2012-02-29 | 2017-12-12 | Valcare, Inc. | Percutaneous annuloplasty system with anterior-posterior adjustment |
US11207176B2 (en) | 2012-03-22 | 2021-12-28 | Boston Scientific Scimed, Inc. | Transcatheter stent-valves and methods, systems and devices for addressing para-valve leakage |
US20130274873A1 (en) | 2012-03-22 | 2013-10-17 | Symetis Sa | Transcatheter Stent-Valves and Methods, Systems and Devices for Addressing Para-Valve Leakage |
EP2644158A1 (fr) * | 2012-03-28 | 2013-10-02 | Sorin Group Italia S.r.l. | Kit pour la manipulation de dispositifs médicaux implantables |
US9301835B2 (en) * | 2012-06-04 | 2016-04-05 | Edwards Lifesciences Corporation | Pre-assembled bioprosthetic valve and sealed conduit |
WO2014022124A1 (fr) | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Conceptions multi-composantes améliorées pour dispositif de récupération de valve cardiaque, structures d'étanchéité et ensemble stent |
WO2014021905A1 (fr) | 2012-07-30 | 2014-02-06 | Tendyne Holdings, Inc. | Systèmes et procédés d'administration améliorée pour valvules prothétiques transcathéter |
US9693862B2 (en) * | 2012-07-31 | 2017-07-04 | Edwards Lifesciences Corporation | Holders for prosthetic heart valves |
US9119713B2 (en) | 2013-03-11 | 2015-09-01 | St. Jude Medical, Cardiology Division, Inc. | Transcatheter valve replacement |
US20140277427A1 (en) | 2013-03-14 | 2014-09-18 | Cardiaq Valve Technologies, Inc. | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
US9730791B2 (en) | 2013-03-14 | 2017-08-15 | Edwards Lifesciences Cardiaq Llc | Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery |
EP2967700B1 (fr) | 2013-03-15 | 2020-11-25 | Valcare, Inc. | Systèmes pour poser des anneaux d'annuloplastie |
US9486306B2 (en) | 2013-04-02 | 2016-11-08 | Tendyne Holdings, Inc. | Inflatable annular sealing device for prosthetic mitral valve |
US11224510B2 (en) | 2013-04-02 | 2022-01-18 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US10463489B2 (en) | 2013-04-02 | 2019-11-05 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US10478293B2 (en) | 2013-04-04 | 2019-11-19 | Tendyne Holdings, Inc. | Retrieval and repositioning system for prosthetic heart valve |
US10813751B2 (en) | 2013-05-22 | 2020-10-27 | Valcare, Inc. | Transcatheter prosthetic valve for mitral or tricuspid valve replacement |
EP3003187B1 (fr) | 2013-05-24 | 2023-11-08 | Valcare, Inc. | Remplacement de valve vasculaire périphérique et cardiaque au moyen d'un anneau de support |
US9610159B2 (en) | 2013-05-30 | 2017-04-04 | Tendyne Holdings, Inc. | Structural members for prosthetic mitral valves |
EP3415120B1 (fr) | 2013-06-25 | 2022-12-14 | Tendyne Holdings, Inc. | Caractéristiques de gestion de thrombus et de conformité structurelle pour valvules cardiaques prothétiques |
US11058417B2 (en) | 2013-06-28 | 2021-07-13 | Valcare, Inc. | Device, system, and method to secure an article to a tissue |
US9561103B2 (en) | 2013-07-17 | 2017-02-07 | Cephea Valve Technologies, Inc. | System and method for cardiac valve repair and replacement |
CA2916955A1 (fr) | 2013-07-26 | 2015-01-29 | Impala, Inc. | Systemes et procedes pour sceller des ouvertures dans une paroi anatomique |
US9895219B2 (en) * | 2013-07-31 | 2018-02-20 | Medtronic Vascular Galway | Mitral valve prosthesis for transcatheter valve implantation |
CN105555231B (zh) | 2013-08-01 | 2018-02-09 | 坦迪尼控股股份有限公司 | 心外膜锚固装置和方法 |
JP6563394B2 (ja) | 2013-08-30 | 2019-08-21 | イェーナヴァルヴ テクノロジー インコーポレイテッド | 人工弁のための径方向に折り畳み自在のフレーム及び当該フレームを製造するための方法 |
US9839511B2 (en) | 2013-10-05 | 2017-12-12 | Sino Medical Sciences Technology Inc. | Device and method for mitral valve regurgitation treatment |
US9393111B2 (en) | 2014-01-15 | 2016-07-19 | Sino Medical Sciences Technology Inc. | Device and method for mitral valve regurgitation treatment |
WO2015058039A1 (fr) | 2013-10-17 | 2015-04-23 | Robert Vidlund | Appareil et procedes d'alignement et de deploiement de dispositifs intracardiaques |
JP6554094B2 (ja) | 2013-10-28 | 2019-07-31 | テンダイン ホールディングス,インコーポレイテッド | 人工心臓弁及び人工心臓弁を送達するシステム及び方法 |
US9526611B2 (en) | 2013-10-29 | 2016-12-27 | Tendyne Holdings, Inc. | Apparatus and methods for delivery of transcatheter prosthetic valves |
EP3062711B1 (fr) | 2013-10-31 | 2023-06-21 | AtriCure, Inc. | Dispositifs d'occlusion l'appendice auriculaire gauche |
WO2015120122A2 (fr) | 2014-02-05 | 2015-08-13 | Robert Vidlund | Appareil et procédés pour la mise en place d'une valve mitrale prothétique par l'artère fémorale |
US9986993B2 (en) | 2014-02-11 | 2018-06-05 | Tendyne Holdings, Inc. | Adjustable tether and epicardial pad system for prosthetic heart valve |
WO2015127283A1 (fr) | 2014-02-21 | 2015-08-27 | Cardiaq Valve Technologies, Inc. | Dispositif d'acheminement pour le déploiement maîtrisé d'une de valvule de substitution |
USD755384S1 (en) | 2014-03-05 | 2016-05-03 | Edwards Lifesciences Cardiaq Llc | Stent |
JP6865037B2 (ja) | 2014-03-10 | 2021-04-28 | テンダイン ホールディングス,インコーポレイテッド | 人工僧帽弁を位置決めするため及び人工僧帽弁のテザーの荷重を監視するためのデバイス及び方法 |
US10675450B2 (en) | 2014-03-12 | 2020-06-09 | Corvia Medical, Inc. | Devices and methods for treating heart failure |
BR102014006114B1 (pt) * | 2014-03-14 | 2022-05-10 | Antônio Francisco Neves Filho | Stent com válvula cardíaca mecânica ou biológica para procedimento de troca de válvula minimamente invasivo e dispositivo aplicador de stent |
EP2918249B1 (fr) | 2014-03-14 | 2020-04-29 | Venus MedTech (HangZhou), Inc. | Système de cathéter supra-claviculaire pour un accès transseptal à l'oreillette gauche et ventricule gauche |
CA3161000A1 (fr) | 2014-05-19 | 2015-11-26 | Edwards Lifesciences Cardiaq Llc | Valvule mitrale de remplacement ayant un rabat annulaire |
EP3171786B1 (fr) | 2014-07-23 | 2020-05-13 | Corvia Medical, Inc. | Dispositifs de traitement d'insuffisance cardiaque |
WO2016093877A1 (fr) | 2014-12-09 | 2016-06-16 | Cephea Valve Technologies, Inc. | Valvules cardiaques de remplacement et leurs procédés d'utilisation et de fabrication |
US20180256311A1 (en) * | 2014-12-19 | 2018-09-13 | National Cerebral And Cardiovascular Center | Substrate for forming artificial valve and artificial valve |
JP6826035B2 (ja) | 2015-01-07 | 2021-02-03 | テンダイン ホールディングス,インコーポレイテッド | 人工僧帽弁、並びにその送達のための装置及び方法 |
EP3884906A1 (fr) | 2015-02-05 | 2021-09-29 | Tendyne Holdings, Inc. | Coussinets épicardiques extensibles et dispositifs et procédé pour les mettre en place |
ES2818128T3 (es) | 2015-04-16 | 2021-04-09 | Tendyne Holdings Inc | Aparato para el suministro y el reposicionamiento de válvulas protésicas transcatéter |
US10441416B2 (en) | 2015-04-21 | 2019-10-15 | Edwards Lifesciences Corporation | Percutaneous mitral valve replacement device |
US10376363B2 (en) | 2015-04-30 | 2019-08-13 | Edwards Lifesciences Cardiaq Llc | Replacement mitral valve, delivery system for replacement mitral valve and methods of use |
CN107530168B (zh) | 2015-05-01 | 2020-06-09 | 耶拿阀门科技股份有限公司 | 在心脏瓣膜替换中具有降低的起搏器比例的装置和方法 |
AU2016262564B2 (en) | 2015-05-14 | 2020-11-05 | Cephea Valve Technologies, Inc. | Replacement mitral valves |
US10849746B2 (en) | 2015-05-14 | 2020-12-01 | Cephea Valve Technologies, Inc. | Cardiac valve delivery devices and systems |
WO2016209970A1 (fr) | 2015-06-22 | 2016-12-29 | Edwards Lifescience Cardiaq Llc | Implant de valve cardiaque pouvant être commandé de manière active et procédés de commande de celui-ci |
US10092400B2 (en) | 2015-06-23 | 2018-10-09 | Edwards Lifesciences Cardiaq Llc | Systems and methods for anchoring and sealing a prosthetic heart valve |
US11026788B2 (en) | 2015-08-20 | 2021-06-08 | Edwards Lifesciences Corporation | Loader and retriever for transcatheter heart valve, and methods of crimping transcatheter heart valve |
US10117744B2 (en) | 2015-08-26 | 2018-11-06 | Edwards Lifesciences Cardiaq Llc | Replacement heart valves and methods of delivery |
US10575951B2 (en) | 2015-08-26 | 2020-03-03 | Edwards Lifesciences Cardiaq Llc | Delivery device and methods of use for transapical delivery of replacement mitral valve |
US10350066B2 (en) | 2015-08-28 | 2019-07-16 | Edwards Lifesciences Cardiaq Llc | Steerable delivery system for replacement mitral valve and methods of use |
US10350047B2 (en) | 2015-09-02 | 2019-07-16 | Edwards Lifesciences Corporation | Method and system for packaging and preparing a prosthetic heart valve and associated delivery system |
US10327894B2 (en) | 2015-09-18 | 2019-06-25 | Tendyne Holdings, Inc. | Methods for delivery of prosthetic mitral valves |
EP4309628A3 (fr) | 2015-12-03 | 2024-04-10 | Tendyne Holdings, Inc. | Éléments de cadre pour valvules mitrales prothétiques |
US10357351B2 (en) | 2015-12-04 | 2019-07-23 | Edwards Lifesciences Corporation | Storage assembly for prosthetic valve |
CA3006010C (fr) | 2015-12-28 | 2023-09-26 | Tendyne Holdings, Inc. | Fermetures de poche auriculaire pour valvules cardiaques prothetiques |
USD815744S1 (en) | 2016-04-28 | 2018-04-17 | Edwards Lifesciences Cardiaq Llc | Valve frame for a delivery system |
US20190117841A1 (en) * | 2016-04-29 | 2019-04-25 | St. Jude Medical, Cardiology Division, Inc. | Method of processing biological tissue |
US10470877B2 (en) | 2016-05-03 | 2019-11-12 | Tendyne Holdings, Inc. | Apparatus and methods for anterior valve leaflet management |
EP3454795B1 (fr) | 2016-05-13 | 2023-01-11 | JenaValve Technology, Inc. | Système d'implantation de prothèse de valve cardiaque pour la pose d'une prothèse de valve cardiaque avec une gaine d'introduction et système de chargement |
US10357363B2 (en) * | 2016-06-09 | 2019-07-23 | Medtronic Vascular, Inc. | Transcatheter valve delivery system with crimped prosthetic heart valve |
EP3468480B1 (fr) | 2016-06-13 | 2023-01-11 | Tendyne Holdings, Inc. | Administration séquentielle de valvule mitrale prothétique en deux parties |
WO2017218877A1 (fr) | 2016-06-17 | 2017-12-21 | Cephea Valve Technologies, Inc. | Dispositifs et systèmes de mise en place de valve cardiaque |
EP3478224B1 (fr) | 2016-06-30 | 2022-11-02 | Tendyne Holdings, Inc. | Valves cardiaques prothétiques et appareil associés de mise en place |
US11065116B2 (en) | 2016-07-12 | 2021-07-20 | Tendyne Holdings, Inc. | Apparatus and methods for trans-septal retrieval of prosthetic heart valves |
US10350062B2 (en) * | 2016-07-21 | 2019-07-16 | Edwards Lifesciences Corporation | Replacement heart valve prosthesis |
CN107753153B (zh) | 2016-08-15 | 2022-05-31 | 沃卡尔有限公司 | 用于治疗心脏瓣膜关闭不全的装置和方法 |
CN109789017B (zh) | 2016-08-19 | 2022-05-31 | 爱德华兹生命科学公司 | 用于置换二尖瓣的可转向递送***和使用方法 |
CN114569289A (zh) | 2016-08-26 | 2022-06-03 | 爱德华兹生命科学公司 | 多部分置换心脏瓣膜假体 |
DE202016105963U1 (de) | 2016-10-24 | 2018-01-25 | Nvt Ag | Intraluminale Gefäßprothese zur Implantation in das Herz oder Herzgefäße eines Patienten |
US10758348B2 (en) | 2016-11-02 | 2020-09-01 | Edwards Lifesciences Corporation | Supra and sub-annular mitral valve delivery system |
US10653523B2 (en) | 2017-01-19 | 2020-05-19 | 4C Medical Technologies, Inc. | Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves |
CA3051272C (fr) | 2017-01-23 | 2023-08-22 | Cephea Valve Technologies, Inc. | Valves mitrales de remplacement |
EP4209196A1 (fr) | 2017-01-23 | 2023-07-12 | Cephea Valve Technologies, Inc. | Valvules mitrales de remplacement |
US10561495B2 (en) | 2017-01-24 | 2020-02-18 | 4C Medical Technologies, Inc. | Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve |
EP3573579B1 (fr) | 2017-01-27 | 2023-12-20 | JenaValve Technology, Inc. | Mimétisme de valve cardiaque |
US10905550B2 (en) | 2017-02-01 | 2021-02-02 | Medtronic Vascular, Inc. | Heart valve prostheses including torque anchoring mechanisms and delivery devices for the heart valve prostheses |
US10788490B2 (en) | 2017-02-28 | 2020-09-29 | St. Jude Medical, Cardiology Division, Inc. | Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits |
US10631968B2 (en) | 2017-03-06 | 2020-04-28 | Edwards Lifesciences Corporation | Humidity-management packaging systems and methods |
US12029647B2 (en) | 2017-03-07 | 2024-07-09 | 4C Medical Technologies, Inc. | Systems, methods and devices for prosthetic heart valve with single valve leaflet |
CN108618871A (zh) | 2017-03-17 | 2018-10-09 | 沃卡尔有限公司 | 具有多方向锚部的二尖瓣或三尖瓣修复*** |
US12036113B2 (en) | 2017-06-14 | 2024-07-16 | 4C Medical Technologies, Inc. | Delivery of heart chamber prosthetic valve implant |
CN110996855B (zh) | 2017-07-06 | 2022-05-06 | 爱德华兹生命科学公司 | 可操纵轨道递送*** |
CN111050702B (zh) | 2017-07-13 | 2022-07-05 | 坦迪尼控股股份有限公司 | 人工心脏瓣膜及用于递送人工心脏瓣膜的设备和方法 |
WO2019045766A1 (fr) | 2017-08-17 | 2019-03-07 | Incubar Llc | Valvule vasculaire prothétique et procédés associés à celle-ci |
EP3675774B1 (fr) | 2017-08-28 | 2023-06-21 | Tendyne Holdings, Inc. | Valvules cardiaques prothétiques dotées d'éléments de couplage d'attache |
CN117481869A (zh) | 2018-01-25 | 2024-02-02 | 爱德华兹生命科学公司 | 在部署后用于辅助置换瓣膜重新捕获和重新定位的递送*** |
US11051934B2 (en) | 2018-02-28 | 2021-07-06 | Edwards Lifesciences Corporation | Prosthetic mitral valve with improved anchors and seal |
JP7170127B2 (ja) | 2018-05-23 | 2022-11-11 | コーシム・ソチエタ・ア・レスポンサビリタ・リミタータ | 移植可能なプロテーゼのためのローディングシステムと関連するローディング方法 |
EP3796867A1 (fr) | 2018-05-23 | 2021-03-31 | Sorin Group Italia S.r.l. | Support pour une prothèse de valvule cardiaque, agencement de stockage pour une prothèse de valvule cardiaque, et kit et procédé de sertissage |
US11857441B2 (en) | 2018-09-04 | 2024-01-02 | 4C Medical Technologies, Inc. | Stent loading device |
US11534300B2 (en) | 2018-12-03 | 2022-12-27 | Valcare, Inc. | Stabilizing and adjusting tool for controlling a minimally invasive mitral / tricuspid valve repair system |
JP7403547B2 (ja) | 2019-01-23 | 2023-12-22 | ニオバスク メディカル リミテッド | 被覆された流動修正装置 |
WO2021011702A1 (fr) | 2019-07-15 | 2021-01-21 | Valcare, Inc. | Élément de bioprothèse transcathéter et structure de support |
EP3831343B1 (fr) | 2019-12-05 | 2024-01-31 | Tendyne Holdings, Inc. | Ancrage tressé pour valvule mitrale |
US11648114B2 (en) | 2019-12-20 | 2023-05-16 | Tendyne Holdings, Inc. | Distally loaded sheath and loading funnel |
JP7483017B2 (ja) * | 2020-01-24 | 2024-05-14 | パッチクランプ メドテック, インコーポレイテッド | 着脱可能な移植片・留め具アセンブリを有する組織修復・シーリングデバイスおよびそれを使用するための方法 |
US11931253B2 (en) | 2020-01-31 | 2024-03-19 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
US11992403B2 (en) | 2020-03-06 | 2024-05-28 | 4C Medical Technologies, Inc. | Devices, systems and methods for improving recapture of prosthetic heart valve device with stent frame having valve support with inwardly stent cells |
US11951002B2 (en) | 2020-03-30 | 2024-04-09 | Tendyne Holdings, Inc. | Apparatus and methods for valve and tether fixation |
US11678980B2 (en) | 2020-08-19 | 2023-06-20 | Tendyne Holdings, Inc. | Fully-transseptal apical pad with pulley for tensioning |
Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156621A (en) | 1988-03-22 | 1992-10-20 | Navia Jose A | Stentless bioprosthetic cardiac valve |
US5336616A (en) * | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5411552A (en) | 1990-05-18 | 1995-05-02 | Andersen; Henning R. | Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis |
US5782914A (en) * | 1996-11-29 | 1998-07-21 | Bio-Vascular, Inc. | Method for preparing heterogeneous tissue grafts |
US6126686A (en) | 1996-12-10 | 2000-10-03 | Purdue Research Foundation | Artificial vascular valves |
US20010039450A1 (en) * | 1999-06-02 | 2001-11-08 | Dusan Pavcnik | Implantable vascular device |
US6425916B1 (en) | 1999-02-10 | 2002-07-30 | Michi E. Garrison | Methods and devices for implanting cardiac valves |
US20020133183A1 (en) | 2000-09-29 | 2002-09-19 | Lentz David Christian | Coated medical devices |
US6458156B1 (en) * | 1996-05-31 | 2002-10-01 | The University Of Western Ontario | Expansible bioprosthetic valve stent |
US20020151958A1 (en) * | 2000-03-03 | 2002-10-17 | Chuter Timothy A.M. | Large vessel stents and occluders |
US20030023303A1 (en) | 1999-11-19 | 2003-01-30 | Palmaz Julio C. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US6534004B2 (en) * | 1998-05-14 | 2003-03-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
US6547827B2 (en) | 1998-09-21 | 2003-04-15 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
US6561970B1 (en) | 1994-07-29 | 2003-05-13 | Edwards Lifesciences Corporation | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods |
US6582462B1 (en) | 1990-05-18 | 2003-06-24 | Heartport, Inc. | Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis |
US20030130729A1 (en) * | 2002-01-04 | 2003-07-10 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
US20030181974A1 (en) * | 2002-03-21 | 2003-09-25 | Hua Xie | Bioprosthesis and method for suturelessly making same |
US6630001B2 (en) * | 1998-06-24 | 2003-10-07 | International Heart Institute Of Montana Foundation | Compliant dehyrated tissue for implantation and process of making the same |
US20030199963A1 (en) * | 2002-04-23 | 2003-10-23 | Numed, Inc. | System for implanting a replacement valve |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20040186558A1 (en) * | 2001-02-05 | 2004-09-23 | Cook Incorporated | Implantable vascular device |
US20040243230A1 (en) * | 2003-05-20 | 2004-12-02 | The Cleveland Clinic Foundation | Apparatus and methods for repair of a cardiac valve |
US20050075725A1 (en) * | 2003-10-02 | 2005-04-07 | Rowe Stanton J. | Implantable prosthetic valve with non-laminar flow |
US6878168B2 (en) * | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US20050137682A1 (en) * | 2003-12-22 | 2005-06-23 | Henri Justino | Stent mounted valve |
US20050137688A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical, A Delaware Corporation | Repositionable heart valve and method |
US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050152881A1 (en) * | 2004-01-09 | 2005-07-14 | Regeneration Technologies, Inc. | Muscle-based grafts/implants |
US20050171599A1 (en) * | 2001-12-20 | 2005-08-04 | White Geoffrey H. | Device for use in intraluminal grafting |
US20050216079A1 (en) | 2000-09-20 | 2005-09-29 | Ample Medical, Inc. | Heart valve annulus device and method of using same |
US6969400B2 (en) * | 1995-12-18 | 2005-11-29 | Cohesion Technologies, Inc. | Synthetic implant with nonimmunogenicity coating |
US20060155363A1 (en) * | 2005-01-10 | 2006-07-13 | Laduca Robert | Apparatus and method for deploying an implantable device within the body |
US20060190074A1 (en) * | 2005-02-23 | 2006-08-24 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
US20060195183A1 (en) | 2005-02-18 | 2006-08-31 | The Cleveland Clinic Foundation | Apparatus and methods for replacing a cardiac valve |
US7125418B2 (en) * | 2002-04-16 | 2006-10-24 | The International Heart Institute Of Montana Foundation | Sigmoid valve and method for its percutaneous implantation |
US20070027460A1 (en) * | 2005-07-27 | 2007-02-01 | Cook Incorporated | Implantable remodelable materials comprising magnetic material |
US20070073392A1 (en) * | 2005-09-21 | 2007-03-29 | Christine Heyninck-Jantz | Composite heart valve apparatus manufactured using techniques involving laser machining of tissue |
US20070100435A1 (en) * | 2003-04-24 | 2007-05-03 | Cook Incorporated | Artificial prostheses with preferred geometries |
WO2008063338A2 (fr) | 2006-10-18 | 2008-05-29 | Buckeye Pharmaceuticals, Llc | Dispositif et procédé d'administration d'un composé chimique |
US20080281411A1 (en) | 2004-03-26 | 2008-11-13 | Eric Berreklouw | Assembly Comprising A Ring For Attachment In A Passage Surrounded By Body Tissue As Well As An Applicator For Fitting The Ring In The Passage |
US7578842B2 (en) * | 2006-10-03 | 2009-08-25 | St. Jude Medical, Inc. | Prosthetic heart valves |
US7648527B2 (en) | 2006-03-01 | 2010-01-19 | Cook Incorporated | Methods of reducing retrograde flow |
US7717951B2 (en) * | 2004-05-06 | 2010-05-18 | Cook Incorporated | Delivery system that facilitates visual inspection of an intraluminal medical device |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4084268A (en) * | 1976-04-22 | 1978-04-18 | Shiley Laboratories, Incorporated | Prosthetic tissue heart valve |
JP2529112B2 (ja) * | 1987-08-31 | 1996-08-28 | 株式会社 高研 | 生体弁 |
US5002566A (en) * | 1989-02-17 | 1991-03-26 | Baxter International Inc. | Calcification mitigation of bioprosthetic implants |
US5824041A (en) * | 1994-06-08 | 1998-10-20 | Medtronic, Inc. | Apparatus and methods for placement and repositioning of intraluminal prostheses |
US5960956A (en) * | 1997-02-19 | 1999-10-05 | St. Jude Medical, Inc. | Storage container |
US5957949A (en) * | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
US6454799B1 (en) * | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US6610088B1 (en) * | 2000-05-03 | 2003-08-26 | Shlomo Gabbay | Biologically covered heart valve prosthesis |
US7510572B2 (en) * | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
WO2002022054A1 (fr) * | 2000-09-12 | 2002-03-21 | Gabbay S | Prothese valvulaire et son procede d'utilisation |
US6591998B2 (en) * | 2000-12-21 | 2003-07-15 | Sulzer Carbomedics Inc. | Leakproof container for implantable prosthetic device |
US7547322B2 (en) * | 2001-07-19 | 2009-06-16 | The Cleveland Clinic Foundation | Prosthetic valve and method for making same |
US20030199971A1 (en) * | 2002-04-23 | 2003-10-23 | Numed, Inc. | Biological replacement valve assembly |
US7008763B2 (en) * | 2002-09-23 | 2006-03-07 | Cheung David T | Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue |
US7699168B2 (en) * | 2004-10-29 | 2010-04-20 | Medtronic, Inc. | Heart valve storage and shipping retainer |
US7513909B2 (en) * | 2005-04-08 | 2009-04-07 | Arbor Surgical Technologies, Inc. | Two-piece prosthetic valves with snap-in connection and methods for use |
US7712606B2 (en) * | 2005-09-13 | 2010-05-11 | Sadra Medical, Inc. | Two-part package for medical implant |
US7569071B2 (en) * | 2005-09-21 | 2009-08-04 | Boston Scientific Scimed, Inc. | Venous valve, system, and method with sinus pocket |
US20070095698A1 (en) * | 2005-10-14 | 2007-05-03 | Cambron Ronald E | Apparatus for storing biological prostheses |
US7815923B2 (en) * | 2005-12-29 | 2010-10-19 | Cook Biotech Incorporated | Implantable graft material |
US9078781B2 (en) * | 2006-01-11 | 2015-07-14 | Medtronic, Inc. | Sterile cover for compressible stents used in percutaneous device delivery systems |
US7757543B2 (en) * | 2006-07-13 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US8876894B2 (en) * | 2006-09-19 | 2014-11-04 | Medtronic Ventor Technologies Ltd. | Leaflet-sensitive valve fixation member |
CN101541354B (zh) * | 2006-10-10 | 2012-11-21 | 西洛诺瓦生物科学公司 | 含聚磷氮烯的生物人工心瓣膜 |
EP2077718B2 (fr) * | 2006-10-27 | 2022-03-09 | Edwards Lifesciences Corporation | Tissu biologique pour implantation chirurgicale |
US8236045B2 (en) * | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
US8105375B2 (en) * | 2007-01-19 | 2012-01-31 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US8357387B2 (en) * | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US8157852B2 (en) * | 2008-01-24 | 2012-04-17 | Medtronic, Inc. | Delivery systems and methods of implantation for prosthetic heart valves |
SI3476368T1 (sl) * | 2008-06-06 | 2020-02-28 | Edwards Lifesciences Corporation | Transkatetrska srčna zaklopka z nizkim profilom |
US8869982B2 (en) * | 2009-12-18 | 2014-10-28 | Edwards Lifesciences Corporation | Prosthetic heart valve packaging and deployment system |
US10959839B2 (en) * | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
US20150122687A1 (en) * | 2013-11-06 | 2015-05-07 | Edwards Lifesciences Corporation | Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage |
WO2018204445A1 (fr) * | 2017-05-02 | 2018-11-08 | Medtronic Vascular Inc. | Emballage pour valvule cardiaque prothétique à l'état de tissu sec |
-
2008
- 2008-01-17 US US12/016,168 patent/US8105375B2/en active Active
- 2008-01-17 WO PCT/US2008/051367 patent/WO2008089365A2/fr active Application Filing
-
2011
- 2011-12-23 US US13/336,974 patent/US20120095551A1/en not_active Abandoned
-
2013
- 2013-04-23 US US13/868,892 patent/US9610160B2/en active Active
-
2017
- 2017-04-03 US US15/478,210 patent/US11547560B2/en active Active
-
2022
- 2022-12-09 US US18/078,769 patent/US20230277315A1/en active Pending
-
2023
- 2023-12-12 US US18/536,798 patent/US20240099840A1/en active Pending
Patent Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156621A (en) | 1988-03-22 | 1992-10-20 | Navia Jose A | Stentless bioprosthetic cardiac valve |
US5411552A (en) | 1990-05-18 | 1995-05-02 | Andersen; Henning R. | Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis |
US7618446B2 (en) | 1990-05-18 | 2009-11-17 | Edwards Lifesciences Ag | Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis |
US6582462B1 (en) | 1990-05-18 | 2003-06-24 | Heartport, Inc. | Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis |
US5336616A (en) * | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US6561970B1 (en) | 1994-07-29 | 2003-05-13 | Edwards Lifesciences Corporation | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods |
US6969400B2 (en) * | 1995-12-18 | 2005-11-29 | Cohesion Technologies, Inc. | Synthetic implant with nonimmunogenicity coating |
US6458156B1 (en) * | 1996-05-31 | 2002-10-01 | The University Of Western Ontario | Expansible bioprosthetic valve stent |
US5782914A (en) * | 1996-11-29 | 1998-07-21 | Bio-Vascular, Inc. | Method for preparing heterogeneous tissue grafts |
US6126686A (en) | 1996-12-10 | 2000-10-03 | Purdue Research Foundation | Artificial vascular valves |
US6534004B2 (en) * | 1998-05-14 | 2003-03-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
US6630001B2 (en) * | 1998-06-24 | 2003-10-07 | International Heart Institute Of Montana Foundation | Compliant dehyrated tissue for implantation and process of making the same |
US6547827B2 (en) | 1998-09-21 | 2003-04-15 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
US6425916B1 (en) | 1999-02-10 | 2002-07-30 | Michi E. Garrison | Methods and devices for implanting cardiac valves |
US20010039450A1 (en) * | 1999-06-02 | 2001-11-08 | Dusan Pavcnik | Implantable vascular device |
US20030023303A1 (en) | 1999-11-19 | 2003-01-30 | Palmaz Julio C. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US20020151958A1 (en) * | 2000-03-03 | 2002-10-17 | Chuter Timothy A.M. | Large vessel stents and occluders |
US20050216079A1 (en) | 2000-09-20 | 2005-09-29 | Ample Medical, Inc. | Heart valve annulus device and method of using same |
US20020133183A1 (en) | 2000-09-29 | 2002-09-19 | Lentz David Christian | Coated medical devices |
US20040186558A1 (en) * | 2001-02-05 | 2004-09-23 | Cook Incorporated | Implantable vascular device |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20050171599A1 (en) * | 2001-12-20 | 2005-08-04 | White Geoffrey H. | Device for use in intraluminal grafting |
US6878168B2 (en) * | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US20030130729A1 (en) * | 2002-01-04 | 2003-07-10 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
US20050021136A1 (en) * | 2002-03-21 | 2005-01-27 | Hua Xie | Method for suturelessly attaching a biomaterial to an implantable bioprosthesis frame |
US20030181974A1 (en) * | 2002-03-21 | 2003-09-25 | Hua Xie | Bioprosthesis and method for suturelessly making same |
US7125418B2 (en) * | 2002-04-16 | 2006-10-24 | The International Heart Institute Of Montana Foundation | Sigmoid valve and method for its percutaneous implantation |
US20030199963A1 (en) * | 2002-04-23 | 2003-10-23 | Numed, Inc. | System for implanting a replacement valve |
US20070100435A1 (en) * | 2003-04-24 | 2007-05-03 | Cook Incorporated | Artificial prostheses with preferred geometries |
US20040243230A1 (en) * | 2003-05-20 | 2004-12-02 | The Cleveland Clinic Foundation | Apparatus and methods for repair of a cardiac valve |
US20050075725A1 (en) * | 2003-10-02 | 2005-04-07 | Rowe Stanton J. | Implantable prosthetic valve with non-laminar flow |
US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050137682A1 (en) * | 2003-12-22 | 2005-06-23 | Henri Justino | Stent mounted valve |
US20050137688A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical, A Delaware Corporation | Repositionable heart valve and method |
US20050152881A1 (en) * | 2004-01-09 | 2005-07-14 | Regeneration Technologies, Inc. | Muscle-based grafts/implants |
US20080281411A1 (en) | 2004-03-26 | 2008-11-13 | Eric Berreklouw | Assembly Comprising A Ring For Attachment In A Passage Surrounded By Body Tissue As Well As An Applicator For Fitting The Ring In The Passage |
US7717951B2 (en) * | 2004-05-06 | 2010-05-18 | Cook Incorporated | Delivery system that facilitates visual inspection of an intraluminal medical device |
US20060155363A1 (en) * | 2005-01-10 | 2006-07-13 | Laduca Robert | Apparatus and method for deploying an implantable device within the body |
US20060195183A1 (en) | 2005-02-18 | 2006-08-31 | The Cleveland Clinic Foundation | Apparatus and methods for replacing a cardiac valve |
US20060190074A1 (en) * | 2005-02-23 | 2006-08-24 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
US20070027460A1 (en) * | 2005-07-27 | 2007-02-01 | Cook Incorporated | Implantable remodelable materials comprising magnetic material |
US20070073392A1 (en) * | 2005-09-21 | 2007-03-29 | Christine Heyninck-Jantz | Composite heart valve apparatus manufactured using techniques involving laser machining of tissue |
US7648527B2 (en) | 2006-03-01 | 2010-01-19 | Cook Incorporated | Methods of reducing retrograde flow |
US7578842B2 (en) * | 2006-10-03 | 2009-08-25 | St. Jude Medical, Inc. | Prosthetic heart valves |
WO2008063338A2 (fr) | 2006-10-18 | 2008-05-29 | Buckeye Pharmaceuticals, Llc | Dispositif et procédé d'administration d'un composé chimique |
Cited By (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790398B2 (en) | 2002-01-04 | 2014-07-29 | Colibri Heart Valve Llc | Percutaneously implantable replacement heart valve device and method of making same |
US9610158B2 (en) | 2002-01-04 | 2017-04-04 | Colibri Heart Valve Llc | Percutaneously implantable replacement heart valve device and method of making same |
US9186248B2 (en) | 2002-01-04 | 2015-11-17 | Colibri Heart Valve Llc | Percutaneously implantable replacement heart valve device and method of making same |
US9554898B2 (en) | 2002-01-04 | 2017-01-31 | Colibri Heart Valve Llc | Percutaneous prosthetic heart valve |
US9125739B2 (en) | 2002-01-04 | 2015-09-08 | Colibri Heart Valve Llc | Percutaneous replacement heart valve and a delivery and implantation system |
US8900294B2 (en) | 2002-01-04 | 2014-12-02 | Colibri Heart Valve Llc | Method of controlled release of a percutaneous replacement heart valve |
US10434218B2 (en) | 2007-06-11 | 2019-10-08 | Edwards Lifesciences Corporation | Pre-stressing and capping bioprosthetic tissue |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US11305036B2 (en) | 2007-06-11 | 2022-04-19 | Edwards Lifesciences Corporation | Bioprosthetic tissue having a reduced propensity for in vivo calcification |
US9029418B2 (en) | 2007-12-21 | 2015-05-12 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US10188511B2 (en) | 2007-12-21 | 2019-01-29 | Edwards Lifesciences Corporation | Bioprosthetic tissue with reduced calcification |
US10966822B2 (en) | 2007-12-21 | 2021-04-06 | Edwards Lifesciences Corporation | Heart valve with reduced calcification |
US9339377B2 (en) | 2008-09-29 | 2016-05-17 | Edwards Lifesciences Cardiaq Llc | Body cavity prosthesis |
US9456896B2 (en) | 2008-09-29 | 2016-10-04 | Edwards Lifesciences Cardiaq Llc | Body cavity prosthesis |
US9597183B2 (en) | 2008-10-01 | 2017-03-21 | Edwards Lifesciences Cardiaq Llc | Delivery system for vascular implant |
US10743987B2 (en) | 2009-03-30 | 2020-08-18 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US8366767B2 (en) | 2009-03-30 | 2013-02-05 | Causper Medical Inc. | Methods and devices for transapical delivery of a sutureless valve prosthesis |
US11045316B2 (en) | 2009-03-30 | 2021-06-29 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US9907650B2 (en) | 2009-03-30 | 2018-03-06 | Suzhou Jiecheng Medical Technology Co., Ltd. | Devices and methods for delivery of valve prostheses |
US20100249918A1 (en) * | 2009-03-30 | 2010-09-30 | Ji Zhang | Devices and methods for delivery of aortic and mitral valve prostheses |
US20100249916A1 (en) * | 2009-03-30 | 2010-09-30 | Ji Zhang | Methods and devices for transapical delivery of a sutureless valve prosthesis |
US20100249915A1 (en) * | 2009-03-30 | 2010-09-30 | Ji Zhang | Valve prosthesis with movably attached claspers with apex |
US8444689B2 (en) | 2009-03-30 | 2013-05-21 | Causper Medical Inc. | Valve prosthesis with movably attached claspers with apex |
US11446144B2 (en) | 2009-03-30 | 2022-09-20 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US20100249917A1 (en) * | 2009-03-30 | 2010-09-30 | Ji Zhang | Methods for Delivery of a Sutureless Pulmonary or Mitral Valve |
US8366768B2 (en) * | 2009-03-30 | 2013-02-05 | Causper Medical Inc. | Methods for delivery of a sutureless pulmonary or mitral valve |
US11589984B2 (en) | 2009-03-30 | 2023-02-28 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US10828156B2 (en) | 2009-03-30 | 2020-11-10 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US8540767B2 (en) | 2009-03-30 | 2013-09-24 | Causper Medical Inc. | Devices and methods for delivery of aortic and mitral valve prostheses |
US10751175B2 (en) | 2009-03-30 | 2020-08-25 | Jc Medical, Inc. | Devices and methods for delivery of valve prostheses |
US9585747B2 (en) | 2009-04-15 | 2017-03-07 | Edwards Lifesciences Cardiaq Llc | Vascular implant |
US9339378B2 (en) | 2009-04-15 | 2016-05-17 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US9339379B2 (en) | 2009-04-15 | 2016-05-17 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US9339380B2 (en) | 2009-04-15 | 2016-05-17 | Edwards Lifesciences Cardiaq Llc | Vascular implant |
US9333074B2 (en) | 2009-04-15 | 2016-05-10 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
US9333073B2 (en) | 2009-04-15 | 2016-05-10 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery method |
US10449042B2 (en) | 2010-05-05 | 2019-10-22 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US11419720B2 (en) | 2010-05-05 | 2022-08-23 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US11432924B2 (en) | 2010-05-05 | 2022-09-06 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US9770329B2 (en) | 2010-05-05 | 2017-09-26 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US9119738B2 (en) | 2010-06-28 | 2015-09-01 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
US9737400B2 (en) | 2010-12-14 | 2017-08-22 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
US10973632B2 (en) | 2010-12-14 | 2021-04-13 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
US9498317B2 (en) | 2010-12-16 | 2016-11-22 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
US11027870B2 (en) | 2010-12-16 | 2021-06-08 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
US9713529B2 (en) | 2011-04-28 | 2017-07-25 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US10537422B2 (en) | 2011-11-23 | 2020-01-21 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11413139B2 (en) | 2011-11-23 | 2022-08-16 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11497602B2 (en) | 2012-02-14 | 2022-11-15 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US10363133B2 (en) | 2012-02-14 | 2019-07-30 | Neovac Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US20130253643A1 (en) * | 2012-03-23 | 2013-09-26 | Sorin Group Italia S.R.L. | Collapsible valve prosthesis |
US9895225B2 (en) * | 2012-03-23 | 2018-02-20 | Sorin Group Italia S.R.L. | Collapsible valve prosthesis |
US10314705B2 (en) | 2012-05-30 | 2019-06-11 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US11389294B2 (en) | 2012-05-30 | 2022-07-19 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US10016275B2 (en) | 2012-05-30 | 2018-07-10 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US10940001B2 (en) | 2012-05-30 | 2021-03-09 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9345573B2 (en) * | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US11617650B2 (en) | 2012-05-30 | 2023-04-04 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9186249B2 (en) | 2012-08-10 | 2015-11-17 | Sorin Group Italia S.R.L. | Valve prosthesis and kit |
US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
US10507104B2 (en) | 2013-03-14 | 2019-12-17 | Suzhou Jiecheng Medical Technology Co., Ltd. | Sutureless valve prosthesis delivery device and methods of use thereof |
US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US10383728B2 (en) | 2013-04-04 | 2019-08-20 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US11389291B2 (en) | 2013-04-04 | 2022-07-19 | Neovase Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US9867700B2 (en) | 2013-05-20 | 2018-01-16 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US10143550B2 (en) | 2013-08-08 | 2018-12-04 | Sorin Group Italia S.R.L. | Heart valve prosthesis |
WO2015031124A1 (fr) * | 2013-08-29 | 2015-03-05 | St. Jude Medical, Cardiology Division, Inc. | Valve de transcathéter à tissu lyophilisé |
US20160199178A1 (en) * | 2013-08-29 | 2016-07-14 | St. Jude Medical, Cardiology Division, Inc. | Transcatheter valve with lyophilized tissue |
US10350064B2 (en) | 2013-09-30 | 2019-07-16 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
US11337810B2 (en) | 2013-11-22 | 2022-05-24 | Edwards Lifesciences Corporation | Valvular insufficiency repair device and method |
US11589988B2 (en) | 2013-11-22 | 2023-02-28 | Edwards Lifesciences Corporation | Valvular insufficiency repair device and method |
US10507106B2 (en) | 2013-11-22 | 2019-12-17 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US11590261B2 (en) | 2014-04-02 | 2023-02-28 | Biotronik Ag | Method for the preparation of biological tissue for dry use in an implant |
EP2926840A1 (fr) | 2014-04-02 | 2015-10-07 | Biotronik AG | Procédé de traitement de tissu biologique pour une utilisation à sec dans un implant |
US10245141B2 (en) | 2014-05-14 | 2019-04-02 | Sorin Group Italia S.R.L. | Implant device and implantation kit |
USRE49792E1 (en) | 2014-05-14 | 2024-01-09 | Corcym S.R.L. | Implant device and implantation kit |
US9532870B2 (en) * | 2014-06-06 | 2017-01-03 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US20150351904A1 (en) * | 2014-06-06 | 2015-12-10 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US10449044B2 (en) | 2016-06-02 | 2019-10-22 | Medtronic Vascular, Inc. | Transcatheter valve delivery system with septum hole closure tip assembly |
US11273035B2 (en) | 2016-06-02 | 2022-03-15 | Medtronic Vascular, Inc. | Occluder |
US11464946B2 (en) | 2016-11-09 | 2022-10-11 | Medtronic Vascular, Inc. | Chordae tendineae management devices for use with a valve prosthesis delivery system and methods of use thereof |
US10493248B2 (en) | 2016-11-09 | 2019-12-03 | Medtronic Vascular, Inc. | Chordae tendineae management devices for use with a valve prosthesis delivery system and methods of use thereof |
US11986388B2 (en) | 2016-11-09 | 2024-05-21 | Medtronic Vascular, Inc. | Valve delivery system having an integral displacement component for managing chordae tendineae in situ and methods of use thereof |
US10368988B2 (en) | 2016-11-09 | 2019-08-06 | Medtronic Vascular, Inc. | Valve delivery system having an integral displacement component for managing chordae tendineae in situ and methods of use thereof |
US11273034B2 (en) | 2016-11-09 | 2022-03-15 | Medtronic Vascular, Inc. | Valve delivery system having an integral displacement component for managing chordae tendineae in situ and methods of use thereof |
US10716668B2 (en) | 2017-04-05 | 2020-07-21 | Medtronic, Inc. | Delivery system with anchoring nosecone and method of delivery |
US11534299B2 (en) | 2017-04-05 | 2022-12-27 | Medtronic, Inc. | Delivery system with anchoring nosecone and method of delivery |
US11832829B2 (en) | 2017-04-20 | 2023-12-05 | Medtronic, Inc. | Stabilization of a transseptal delivery device |
US12023416B2 (en) | 2017-05-31 | 2024-07-02 | Edwards Lifesciences Corporation | Collagen fibers and articles formed therefrom |
US11135060B2 (en) | 2017-08-24 | 2021-10-05 | Medtronic Vascular, Inc. | Transseptal delivery systems having a deflecting segment and methods of use |
US11395726B2 (en) | 2017-09-11 | 2022-07-26 | Incubar Llc | Conduit vascular implant sealing device for reducing endoleaks |
US11071846B2 (en) | 2017-09-14 | 2021-07-27 | Medtronic Vascular, Inc. | Deflection catheter for aiding in bending of a catheter |
US10806574B2 (en) | 2017-11-20 | 2020-10-20 | Medtronic Vascular, Inc. | Delivery systems having a temporary valve and methods of use |
US11833044B2 (en) | 2017-11-20 | 2023-12-05 | Medtronic Vascular, Inc. | Delivery systems having a temporary valve and methods of use |
US11357626B2 (en) | 2018-01-07 | 2022-06-14 | Jc Medical, Inc. | Heart valve prosthesis delivery system |
US11285001B2 (en) | 2018-01-07 | 2022-03-29 | Jc Medical, Inc. | Heart valve prosthesis delivery system |
US11083577B2 (en) | 2018-01-07 | 2021-08-10 | Jc Medical, Inc. | Heart valve prosthesis |
US11090156B2 (en) | 2018-01-07 | 2021-08-17 | Jc Medical, Inc. | Heart valve prosthesis delivery system |
US11123189B2 (en) | 2018-01-07 | 2021-09-21 | Jc Medical, Inc. | Heart valve prosthesis delivery system |
US11253363B2 (en) | 2018-01-07 | 2022-02-22 | Jc Medical Inc. | Heart valve prosthesis |
US11819407B2 (en) | 2018-01-07 | 2023-11-21 | Jc Medical, Inc. | Heart valve prosthesis delivery system |
US12023417B2 (en) | 2018-01-23 | 2024-07-02 | Edwards Lifesciences Corporation | Method for pre-stretching implantable biocompatible materials, and materials, and devices produced thereby |
US10925728B2 (en) | 2018-02-22 | 2021-02-23 | Medtronic Vascular, Inc. | Prosthetic heart valve delivery systems and methods |
US11504231B2 (en) | 2018-05-23 | 2022-11-22 | Corcym S.R.L. | Cardiac valve prosthesis |
US11969341B2 (en) | 2018-05-23 | 2024-04-30 | Corcym S.R.L. | Cardiac valve prosthesis |
US11517428B2 (en) | 2018-11-01 | 2022-12-06 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
US11612482B2 (en) | 2019-03-06 | 2023-03-28 | Medtronic, Inc. | Trans-septal delivery system and methods of use |
WO2022090418A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de mise en forme tridimensionnelle d'un tissu ou d'un composant de tissu |
WO2022090417A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de liaison/jonction sans couture de tissus comprenant des groupes réticulables |
WO2022090419A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé de traitement de tissu non réticulé |
WO2022090420A1 (fr) | 2020-10-30 | 2022-05-05 | Biotronik Ag | Procédé pour la production de tissus réticulés et éventuellement façonnés avec ajustement sélectif de l'épaisseur, de la forme et/ou de la flexibilité |
WO2023208607A1 (fr) | 2022-04-29 | 2023-11-02 | Biotronik Ag | Procédé de production de tissu biologique |
Also Published As
Publication number | Publication date |
---|---|
US20170266002A1 (en) | 2017-09-21 |
US20130238088A1 (en) | 2013-09-12 |
US20240099840A1 (en) | 2024-03-28 |
US9610160B2 (en) | 2017-04-04 |
US20080177381A1 (en) | 2008-07-24 |
US11547560B2 (en) | 2023-01-10 |
WO2008089365A2 (fr) | 2008-07-24 |
US20230277315A1 (en) | 2023-09-07 |
US20120095551A1 (en) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240099840A1 (en) | Method for implanting a cardiovascular valve | |
US20220110748A1 (en) | Apparatus and method for replacing a diseased cardiac valve | |
US10939999B2 (en) | Apparatus and method for replacing a diseased cardiac valve | |
US8414641B2 (en) | Valve with delayed leaflet deployment | |
US7524331B2 (en) | Catheter delivered valve having a barrier to provide an enhanced seal | |
US7591848B2 (en) | Riveted stent valve for percutaneous use | |
AU2014280916B2 (en) | Apparatus and method for replacing a diseased cardiac valve | |
BR102022003127A2 (pt) | Stent aórtico | |
Flecher et al. | In vitro study of percutaneous aortic valve replacement: selection of a tissue valve |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE CLEVELAND CLINIC FOUNDATION, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAVIA, JOSE LUIS;CHEN, JI-FENG;REEL/FRAME:020761/0466;SIGNING DATES FROM 20080205 TO 20080402 Owner name: THE CLEVELAND CLINIC FOUNDATION, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAVIA, JOSE LUIS;CHEN, JI-FENG;SIGNING DATES FROM 20080205 TO 20080402;REEL/FRAME:020761/0466 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |
|
AS | Assignment |
Owner name: EDWARDS LIFESCIENCES CORPORATION, CALIFORNIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:THE CLEVELAND CLINIC FOUNDATION;REEL/FRAME:067429/0539 Effective date: 20240223 |